Aratana Therapeutics (PETX) Gross Profit Margin starting from the first quarter 2019 to first quarter 2018, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Aratana Therapeutics, Inc.  (PETX)


Aratana Therapeutics's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PETX Gross Profit Margin (Mar 31 2019)
Q1 		(Dec 31 2018)
Q4 		(Sep 30 2018)
Q3 		(Jun 30 2018)
Q2 		(Mar 31 2018)
Q1
Y / Y Revenue Change 82.04 %
Seq. Revenue Change 50.02 %
Revenue In Millions $7.36
Gross Profit Margin 79.36 %
Gross Profit Margin Total Ranking # 567
Gross Profit In Millions $5.84
Y / Y Gross Profit Change 66.55 %
Seq. Gross Profit Change 173.46 %


Commenting First Quarter 2019 Gross Profit Margin
Aratana Therapeutics, Inc. Gross Profit grew by 173.46 % in Q1 sequentially to 6 millions, while Revenue increased by 50.02 %, this led to improvement in the company's Gross Profit Margin to 79.36 %, above the Aratana Therapeutics, Inc. average Gross Profit Margin.


Observing first quarter 2019 results within Major Pharmaceutical Preparations industry 67 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 567, from total ranking in the previous quarter at 2101.
Learn about Gross Margin
PETX's Gross Profit Margin first quarter 2019 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 68
Healthcare Sector # 124
Overall # 551

Gross Profit Margin Statistics
High Average Low
95.42 % 56.82 % 12.2 %
(Jun 30 2016)   (Dec 31 2013)


PETX Gross Income Trends • More of PETX's Profitabilty Ratios • PETX Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
PETX's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
PETX's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for PETX's Competitors
Gross Profit Margin Profit Margin for Aratana Therapeutics's Suppliers
Gross Profit Margin Profit Margin for PETX's Customers

You may also want to know
PETX's Annual Growth Rates PETX's Profitability Ratios PETX's Asset Turnover Ratio PETX's Dividend Growth
PETX's Roe PETX's Valuation Ratios PETX's Financial Strength Ratios PETX's Gross Profit Growth
PETX's Roa PETX's Inventory Turnover Ratio PETX's Growth Rates PETX's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Mar 31 2019, within Major Pharmaceutical Preparations Industry Gross Profit MarginMar 31 2019 MRQ Gross ProfitMar 31 2019 MRQ Revenue
Ionis Pharmaceuticals Inc   99.65 %$ 296.173  Millions$ 297.214  Millions
Omeros Corporation  99.40 %$ 21.648  Millions$ 21.779  Millions
American Brivision (holding) Corp  99.29 %$ 0.211  Millions$ 0.212  Millions
Rigel Pharmaceuticals Inc  99.15 %$ 12.517  Millions$ 12.624  Millions
Intercept Pharmaceuticals inc   98.90 %$ 51.678  Millions$ 52.252  Millions
Agios Pharmaceuticals Inc   98.90 %$ 29.893  Millions$ 30.227  Millions
Sangui Biotech International Inc  98.77 %$ 0.008  Millions$ 0.008  Millions
Akcea Therapeutics Inc   98.51 %$ 161.372  Millions$ 163.816  Millions
Ironwood Pharmaceuticals inc   98.48 %$ 67.687  Millions$ 68.730  Millions
Stemline Therapeutics Inc  98.30 %$ 4.963  Millions$ 5.049  Millions
Corcept Therapeutics Inc  98.09 %$ 63.589  Millions$ 64.829  Millions
Ultragenyx Pharmaceutical Inc   97.51 %$ 17.720  Millions$ 18.172  Millions
Travere Therapeutics Inc   97.43 %$ 38.553  Millions$ 39.570  Millions
Bellicum Pharmaceuticals Inc   96.76 %$ 0.896  Millions$ 0.926  Millions
Celgene Corp  96.52 %$ 3,885.000  Millions$ 4,025.000  Millions
Adamas Pharmaceuticals Inc  96.46 %$ 11.252  Millions$ 11.665  Millions
Regeneron Pharmaceuticals Inc   95.86 %$ 1,640.900  Millions$ 1,711.800  Millions
Supernus Pharmaceuticals inc   95.69 %$ 81.790  Millions$ 85.474  Millions
Ptc Therapeutics inc   95.57 %$ 51.207  Millions$ 53.583  Millions
Assertio Holdings inc   95.55 %$ 55.354  Millions$ 57.929  Millions
Skinvisible Inc   95.51 %$ 0.008  Millions$ 0.008  Millions
Acadia Pharmaceuticals Inc   95.31 %$ 60.009  Millions$ 62.959  Millions
Intelgenx Technologies Corp   94.23 %$ 0.392  Millions$ 0.416  Millions
Lexicon Pharmaceuticals Inc   94.00 %$ 8.663  Millions$ 9.216  Millions
Alexion Pharmaceuticals Inc   92.48 %$ 1,054.600  Millions$ 1,140.400  Millions
United Therapeutics Corporation  91.97 %$ 333.500  Millions$ 362.600  Millions
Puma Biotechnology Inc   91.94 %$ 91.082  Millions$ 99.067  Millions
Oramed Pharmaceuticals Inc  91.74 %$ 0.611  Millions$ 0.666  Millions
Zyla Life Sciences  91.42 %$ 5.724  Millions$ 6.261  Millions
Siga Technologies Inc  91.25 %$ 9.544  Millions$ 10.459  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.